The Scientist

» drug development and neuroscience

Most Recent

image: Opinion: New Models for ASD

Opinion: New Models for ASD

By | May 14, 2015

The study of mini “brains” in a dish, derived from patient cells, offers a novel approach for autism spectrum disorder research.

0 Comments

image: Targeting Protein Domains with CRISPR

Targeting Protein Domains with CRISPR

By | May 13, 2015

Researchers use the genome-editing tool to mutate binding pockets and identify potential anti-cancer drug targets.

0 Comments

image: Mouse Mind Control

Mouse Mind Control

By | May 4, 2015

Researchers use chemicals to manipulate the behavior of mice.

1 Comment

image: Capsule Reviews

Capsule Reviews

By | May 1, 2015

The Genealogy of a Gene, On the Move, The Chimp and the River, and Domesticated

0 Comments

image: Targeted Information in the Rat Brain

Targeted Information in the Rat Brain

By | April 30, 2015

A study shows that the hippocampus selects which information to send, and where, during different behaviors.

0 Comments

image: One-Man Tinnitus Map

One-Man Tinnitus Map

By | April 26, 2015

Researchers probe the neural roots of the ear-ringing condition in a man undergoing brain surgery.

0 Comments

image: RNA Ebola Drug Clears Animal Study

RNA Ebola Drug Clears Animal Study

By | April 24, 2015

The short interfering RNA-based therapy TKM-Ebola protects monkeys from the viral strain still circulating in West Africa.

0 Comments

image: FDA Calls for Data on ALS Drug

FDA Calls for Data on ALS Drug

By | April 21, 2015

In the midst of a debate about an experimental drug’s early approval, the US Food and Drug Administration requests that full trial results be released.

1 Comment

image: Why DBS Works for Parkinson’s?

Why DBS Works for Parkinson’s?

By | April 14, 2015

Deep-brain stimulation may effectively treat slow movement, tremor, and rigidity in Parkinson’s patients by reducing synchronicity of neural activity in the motor cortex.

0 Comments

image: ALS Drug Access Debated

ALS Drug Access Debated

By | April 7, 2015

Biotech company Genervon has requested accelerated approval for its experimental ALS drug after a small but promising Phase 2 trial. Patients advocate for its acceptance, while researchers urge caution.

2 Comments

Popular Now

  1. Gut Microbes Linked to Neurodegenerative Disease
  2. Infant Microbiome: Vaginal Delivery Versus C-Section
  3. Top 10 Innovations 2016
    Features Top 10 Innovations 2016

    This year’s list of winners celebrates both large leaps and small (but important) steps in life science technology.

  4. Opinion: WHO’s Silence on Cannabis
Rockland